ArticleVaccine2017
Protective efficacy of multivalent replication-abortive vaccine strains in horses against African horse sickness virus challenge.
Article in Vaccine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- Re-parameterization of a mathematical model of African horse sickness virus using data from a systematic literature search.Transboundary and emerging diseases · 2022Pooled it
- Preliminary Assessment on Pathogenicity of an African Horse Sickness Virus Serotype 1 Strain in Guinea Pigs and Horses.Microorganisms · 2026Article
- Multivalent Disabled Infectious Single Animal (DISA)-DIVA vaccine for all nine serotypes of African horse sickness virus (AHSV) is broadly protective in IFNAR (-/-) mice.Veterinary research · 2026Article
- Development of an African horse sickness VP6 DIVA diagnostic ELISA.Virology journal · 2025Article
- The Potential of Plant-Produced Virus-like Particle Vaccines for African Horse Sickness and Other Equine Orbiviruses.Pathogens (Basel, Switzerland) · 2024Review
- Investigating the Role of African Horse Sickness Virus VP7 Protein Crystalline Particles on Virus Replication and Release.Viruses · 2022Article
- Article
- Article
- African horse sickness in Thailand: Challenges of controlling an outbreak by vaccination.Equine veterinary journal · 2021Article
- Inhibition of Orbivirus Replication by Aurintricarboxylic Acid.International journal of molecular sciences · 2020Article
- Reverse genetics approaches: a novel strategy for African horse sickness virus vaccine design.Current opinion in virology · 2020Review
- Plant-produced chimeric virus-like particles - a new generation vaccine against African horse sickness.BMC veterinary research · 2019Article
- Review
- Article
- Safety and immunogenicity of plant-produced African horse sickness virus-like particles in horses.Veterinary research · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 2 countries.
Funding
Abstract
African horse sickness virus (AHSV) is an orbivirus, a member of the Reoviridae family. Nine different serotypes have been described so far. AHSV is vectored by Culicoides spp. to equids, causing high mortality, particularly in horses, with considerable economic impacts. For development of a safe attenuated vaccine, we previously established an efficient reverse genetics (RG) system to generate Entry Competent Replication-Abortive (ECRA) virus strains, for all nine serotypes and demonstrated the vaccine potential of these strains in type I interferon receptor (IFNAR)-knockout mice. Here, we evaluated the protective efficacies of these ECRA viruses in AHSV natural hosts. One monoserotype (ECRA.A4) vaccine and one multivalent cocktail (ECRA.A1/4/6/8) vaccine were tested in ponies and subsequently challenged with a virulent AHSV4. In contrast to control animals, all vaccinated ponies were protected and did not develop severe clinical symptoms of AHS. Furthermore, the multivalent cocktail vaccinated ponies produced neutralizing antibodies against all serotypes present in the cocktail, and a foal born during the trial was healthy and had no viremia. These results validate the suitability of these ECRA strains as a new generation of vaccines for AHSV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.